Outcomes of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) evaluation vary with technique, needles, and methods of specimen evaluation. We performed a direct comparison of diagnostic yields of EUS-FNA samples collected using different gauge needles (22-vs 25-gauge), with or without suction.
See editorial on page 1712. E ndoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is integral to diagnosis and staging of pancreatic cancer. However, EUS-FNA is a multi-step process involving several factors that determine procedural outcomes: degree of technical difficulty, size of FNA needle, use of a stylet in needle assembly, application of suction to aspirate tissue, different techniques of needle movement through the lesion, onsite or offsite specimen processing, and finally, the experience and skills of an endosonographer. This likely contributes to the wide variation in reported outcomes for diagnostic sensitivity of EUS in pancreatic cancer, ranging from 50% to 100%. 1 Although some technical questions such as the utility of a stylet and need for "fanning" a needle during tissue acquisition have been addressed in randomized trials, 2, 3 other procedural techniques and methods adopted for specimen evaluation are not standardized. Two key procedural techniques that require further evaluation are the choice of needle size and the use of suction for tissue procurement. Another major determinant of diagnostic sensitivity of EUS-FNA is how the specimen is evaluated, whether the assessment is made onsite with rapid onsite evaluation (ROSE) or offsite by using cytology slides or cell block technique.
EUS-FNA of pancreatic masses is usually performed with either a 22-gauge (G) or 25G needle. Five metaanalyses have compared the diagnostic performance of these needles; 2 suggested that 25G needles have better diagnostic sensitivity, 4, 5 and 3 observed no such difference. [6] [7] [8] Therefore, it remains unclear whether the diagnostic performance of both 22G and 25G needles are similar or if one may be more advantageous.
Suction is commonly used during EUS-FNA to increase tissue yield. However, application of suction often results in more specimen bloodiness, which can affect diagnostic interpretation. The utility of suction in EUS-FNA of pancreatic masses therefore remains unclear, with one randomized trial reporting superior diagnostic sensitivity and accuracy with use of suction 9 and another prospective study showing more inadequate and bloody samples. 10 A major limitation of EUS-FNA is that the diagnostic sensitivity is dependent on availability of a cytopathologist to render ROSE. ROSE improves diagnostic yield, decreases number of inadequate or unsatisfactory samples, and limits the number of FNA passes required to establish diagnosis. 11 Unfortunately, because of limited resources and financial constraints, ROSE is not universally available, and a common alternative technique is to prepare a cell block for offsite assessment. In this method, the FNA specimen is collected in a preservative to create a tissue pellet (cell block), which is later processed for histologic interpretation. In a retrospective study of 122 patients with pancreatic masses who underwent EUS-FNA with a 22G needle, the diagnostic accuracy of cell block was 78%. 12 In a randomized trial of 62 patients with pancreatic masses who were sampled by using a 25G needle without suction, the cell block diagnostic yield was 80.6%. 13 It therefore remains unclear whether using a 22G needle with suction will improve cell block yield and possibly obviate the need for ROSE.
Several critical questions pertaining to EUS-FNA of pancreatic masses remain unanswered. It is unlikely that a single strategy for tissue procurement or evaluation will suit all lesions or every EUS center. Instead, tailoring tissue procurement techniques to the methods used for specimen evaluation (cell block versus ROSE) may improve EUS-FNA outcomes. To test this concept, we designed a 4-arm randomized trial with long-term follow-up. The study hypothesis was that a 22G needle with suction will procure more tissue, improve cell block diagnostic yield at centers without access to ROSE, and establish onsite diagnostic adequacy with fewer passes. The primary endpoint was therefore to compare the diagnostic accuracy of cell block in patients undergoing EUS-FNA of pancreatic masses by using 22G needle with suction, 22G needle without suction, 25G needle with suction, or 25G needle without suction. The secondary endpoints were to compare operating characteristics of ROSE and EUS-FNA, number of passes to establish onsite diagnostic adequacy, specimen bloodiness, adverse events, and technical failure.
Methods

Patients and Settings
This was a randomized trial conducted at Florida Hospital, Orlando. All patients aged 19 years and older with suspected solid pancreatic mass lesions that were identified on computed tomography scan and referred for EUS-FNA were eligible for participation. Patients were excluded if a pancreatic mass lesion was not seen at EUS, the mass had a cystic component, or if the coagulation parameters were abnormal. Written informed consents were obtained from all patients. All authors had access to the study data and have reviewed and approved the final manuscript.
Randomization and Masking
Computer-generated randomization assignments were obtained by using the block randomization method and placed in sequentially numbered, sealed, opaque envelopes to be opened by the endoscopy nurse intraprocedurally when patients met inclusion criteria. Patients were randomized equally to 1 of 4 cohorts (1:1:1:1 allocation): 22G with suction, 22G without suction, 25G with suction, and 25G without suction.
Procedural Technique
All procedures were performed by using a linear array echoendoscope (Olympus GF-UCT180; Olympus America Inc, Center Valley, PA) after administration of propofol by using 22G or 25G needles (Expect; Boston Scientific Corporation, Natick, MA), with or without suction, by 1 of 4 experienced endosonographers (>700 EUS procedures/year).
During EUS-FNA, the stylet was removed after puncturing the pancreatic mass and sampled by using the fanning technique. 3 The stylet was not reintroduced after the first FNA pass to minimize bloodiness. 2 In patients randomized to undergo FNA by using suction, after puncturing the pancreatic mass, 10 mL dry negative suction was applied during the fanning maneuver and released before removal of the needle. Immediate adverse events were documented at the time of the procedure and late adverse events by telephone followup at 24 hours and 10 days after the procedure.
Rapid Onsite Evaluation
To avoid potential bias, specimens from first 2 passes were collected for cell block in a methanol-based preservative (CytoLyt; Holgic Inc, Marlborough, MA). Subsequent passes were performed for assessment by ROSE. Air-dried and wet-fixed smears were prepared on site. Air-dried smears were stained with Diff-Quik and immediately reviewed by an onsite (cyto)pathologist blinded to the needle type and technique adopted to establish onsite diagnostic adequacy and specimen bloodiness. Wet-fixed smears were immersed in 95% ethyl alcohol for subsequent Papanicolaou staining.
A maximum of 8 passes (excluding cell block) were performed, and if onsite assessment was non-diagnostic, the patient underwent further FNA passes by using an alternate needle with or without application of suction at discretion of the endosonographer. However, if diagnostic adequacy was established at initial attempt, the procedure was terminated, and the number of passes performed was documented.
Cell Block
In the laboratory, the preservative solution containing the collected specimen was centrifuged. If the specimen quantity was sufficient, the supernatant was removed, and equal drops of plasma and thrombin were added to form a tissue pellet that was placed in a cassette and immersed in 10% formalin for fixation. After dehydration and paraffin embedding, the tissue block was cut into 6-mm-thick sections, stained with hematoxylin and eosin, and evaluated for the presence of histologic tissue. When required, immunohistochemical or special staining was performed for diagnosis and differentiation of morphologically challenging lesions. All slides were reviewed by 2 experienced pathologists who were blinded to the findings at ROSE.
Definitions
Final diagnosis of malignancy was defined by 1 or more of the following criteria: (1) histologic evidence of malignancy in surgical specimen, (2) progression of lesion or presence of metastases on follow-up imaging, (3) cancer-related death within 12 months of EUS-FNA, and (4) follow-up with patient's referring physician, confirming death or disease progression due to pancreatic cancer. Lesions were considered benign if they met 1 or more of the following criteria: (1) surgical pathology reported no malignancy, (2) follow-up imaging at 12 months reported a stable mass with no metastases, and (3) patient well-being at 1-year follow-up with the primary care physician. The reference standard for classification of disease included the following: surgical resection, death from disease progression, repeat radiologic, and/or clinical follow-up. Follow-up was performed by the study coordinator at 6 months and 1 year.
Diagnostic cell block was defined as presence of histologic core tissue that was representative of findings at final diagnosis. Non-diagnostic cell block was defined as suboptimal or insufficient material that was not representative of final diagnosis. Diagnostic adequacy at ROSE was defined as proportion of patients in whom the FNA sample was of sufficient quality to render a preliminary diagnosis that was interpreted as benign, malignant, reactive atypia, or non-diagnostic.
14 Diagnostic failure by ROSE (nondiagnostic) was defined as the inability to obtain sufficient material for assessment of onsite diagnosis adequacy despite 8 passes.
Technical failure was defined as needle malfunction before an onsite assessment could be rendered. Specimen bloodiness was categorized on the basis of percentage of blood in the microscopic field: mild, <33%; moderate, 33%-66%; and severe, >66%. Adverse events were defined according to a predefined consensus. 15 
Outcome Measures
The primary outcome was to compare proportion of diagnostic cell block obtained during EUS-FNA of pancreatic masses between the 4 cohorts. Secondary outcomes were to compare operating characteristics (sensitivity, specificity, negative predictive value [NPV], positive predictive value, accuracy, positive and negative likelihood ratios) of cell block, ROSE, and EUS-FNA (combined cell block and ROSE) on the basis of the final diagnosis as defined above. Other outcomes included the number of passes to establish onsite diagnostic adequacy, specimen bloodiness, technical failure, and adverse events. Specimen bloodiness was categorized as mild, moderate, or severe as reported previously. 13 
Sample Size Calculation
A two-tailed sample size calculation was performed with type I error rate (a) set at 0.05 to attain 80% power for detecting a difference of 15% in attaining a diagnostic cell block with and without suction (95% with suction, 80% without suction). This resulted in sample size of 88 per group, with total of 4 groups (22G with suction, 22G without suction, 25G with suction, and 25G without suction). Consequently, this resulted in overall sample size of 176 patients for the 22G needle group and 176 patients for the 25G needle group, which in turn translated to power of 95% based on attainment of diagnostic cell block in 93.8% with the 22G needle 16 and 80.6% with the 25G needle. 13 
Statistical Analysis
Baseline characteristics of patient population, pancreatic mass lesions, technical details, and procedure outcomes were summarized as means (with standard deviation) and medians (with interquartile range) for continuous data and as frequencies and proportions for categorical data. Operating characteristics were also calculated. For comparison of categorical data, c 2 or Fisher exact test was used as indicated, whereas the two-sample t test, Wilcoxon rank sum test, or KruskalWallis test was used as appropriate for comparison of continuous data. Statistical significance was determined at P < .05. Analysis of the outcome measures was performed by using both the intention-to-treat and per protocol methods. All statistical analyses were performed by using Stata 14 (Stata Corp, College Station, TX). The results are reported in accordance to the Consolidated Standards of Reporting Trials 2010 guidelines and Standards for Reporting of Diagnostic Accuracy guideline.
Results
Of 519 consecutive patients screened for participation in this study between July 2014 and February 2016, 167 were excluded (Supplementary Figure 1) . A total of 352 patients constituted the study cohort and were randomized to 1 of 4 groups (Supplementary Figure 1) . Similar results were observed between the intention-totreat and per protocol analyses of all outcome measures.
Patient Demographics and Tumor Characteristics
There was no significant difference in patient demographics or tumor characteristics between cohorts (Table 1) . Final diagnosis was malignancy in 269 patients (76.4%), other neoplasia in 23 patients (6.5%), and benign disease in 60 patients (17.0%).
Cell Block
Histologic tissue was present at cell block (diagnostic adequacy) in 73.0% of the entire study cohort (Table 2 ) and in 80.4% of malignant lesions (Table 3) . Diagnostic accuracy of cell block for all lesions and for malignant lesions was 71.9% (95% confidence interval [CI], 66.9%-76.5%) and 79.0% (95% CI, 73.8%-83.6%), respectively (Table 4 ). There was no significant difference in operating characteristics of cell block between the 4 cohorts, with exception of NPV. Despite this significance, the NPV was suboptimal for all groups. The overall NPV of cell block for 22G needles compared with 25G needles was 29.7% (95% CI, 18.9%-42.4%) vs 6.9% (95% CI, 1.9%-16.7%), P ¼ .001. The use of suction did not improve the diagnostic accuracy of cell block for both 22G and 25G needles. Tumor marker expression in cell block specimens was possible in 43 of 48 patients (89.6%), with no significant difference between cohorts (Table 2) .
Rapid Onsite Evaluation
Diagnostic adequacy was established by ROSE in 350 of 352 patients (99.4%), with no significant difference between cohorts (Table 2) . In 2 patients, ROSE was non-diagnostic despite performing 8 passes by using the 22G needle with suction, and the cell block was nondiagnostic as well.
Overall diagnostic accuracy and sensitivity of ROSE were greater than 95% for all cohorts except the 22G needle when used in conjunction with suction (92.0% and 92.5%, respectively); however, this difference was not statistically significant (Table 5) . On subgroup analysis, the diagnostic accuracy of ROSE for detecting malignancy was 95.5% (95% CI, 92.7%-97.4%). There were 16 cases (4.5%) of false-positive or false-negative diagnoses at follow-up, with no significant difference between cohorts. In 3 of these 16 patients, the cell block was diagnostic and revealed chronic pancreatitis in 2 patients and pancreatic adenocarcinoma in 1 patient. 
Median Number of Fine-needle Aspiration Passes and Specimen Bloodiness at Rapid Onsite Evaluation
Median number of passes required to achieve onsite diagnostic adequacy was significantly higher for the 22G needle when used in conjunction with suction compared with other cohorts (median, 2 vs 1 pass; P ¼ .003) ( Table 2 ). In addition, specimens were significantly more bloody when using suction compared with no suction (P ¼ .001), particularly with 22G needles (P ¼ .01).
Technical Failure
Technical failure was observed in 13 of 352 patients (3.7%) ( Table 2 ). Twelve of 13 events occurred with use of suction, and most technical failures were due to a bent needle tip that precluded adequate endosonographic visualization of the needle during FNA passes. Technical failure was significantly more frequent when using suction (0.6% vs 6.8%, P ¼ .002) and particularly with the 25G needle when performing transduodenal FNA passes (P ¼ .019). Only 2 technical failures were observed when performing transgastric FNAs, and both occurred when using a 22G needle with suction (Supplementary Table 1 ).
Adverse Events
Adverse events were encountered in 24 of 352 patients (6.8%), with no significant difference between cohorts ( Table 2 ). All adverse events were mild and included bleeding, pancreatitis, fever, post-procedure abdominal pain, infection, and vomiting. Seven patients required hospitalization for management of infection (n ¼ 2), post-procedure pancreatitis (n ¼ 3), and abdominal pain (n ¼ 2) that were managed conservatively.
Endoscopic Ultrasound-guided Fine-needle Aspiration
Overall diagnostic accuracy of EUS-FNA was 96.6%, with no significant difference between cohorts (Table 6 ). With exception of the 22G needle with suction cohort (diagnostic accuracy of 92.0%), diagnostic accuracy was between 96.6% and 98.9% for other groups. On subgroup analysis, diagnostic accuracy (P ¼ .004) and sensitivity (P ¼ .026) of EUS-FNA were negatively impacted by use of suction at transduodenal FNA passes (Supplementary Table 2 ). Operating characteristics of cell block, ROSE, and EUS-FNA are shown in Supplementary Figure 2 . 
Follow-up
All patients were followed up to 12 months postprocedure. Of the 291 patients with neoplastic disease, 167 were deceased, 119 were alive, and 5 were lost to follow-up. Of 119 patients who were alive, 61 had undergone surgery, 42 had clinical-radiologic evidence of disease progression, 13 were undergoing chemoradiation, and 3 had no evidence of disease progression either clinically or radiologically (false positives). Two patients who underwent pancreatic resection for cancer had benign disease on surgical histology (false positives).
Of the 61 patients with benign disease after EUS evaluation, 50 had no clinical or radiologic progression of disease at follow-up, and 11 had pancreatic cancer (false negatives) that were proven by death in 3 patients, clinical and radiologic evidence of disease progression in 5, surgery in 2, and by repeat EUS-FNA in 1 patient.
Discussion
The present study confirms that outcomes of EUS-FNA of pancreatic masses are reliant on technical factors and methods adopted for specimen evaluation. Tailoring procedural aspects to specimen evaluation techniques is likely to yield better outcomes.
We observed no significant difference in the diagnostic accuracy of cell block between cohorts despite performing 2 dedicated passes in every subject. This likely was because of paucicellular tissue procurement and a proportion of the collected tissue being consumed, distorted, or lost during automated processing and sectioning during cell block preparation. Therefore, for institutions that depend exclusively on cell block, either the 22G or 25G needle may be used, provided sufficient number of passes are made to maximize diagnostic yield.
In the present study, the accuracy of ROSE for detecting malignancy was 96%, and the non-diagnostic rate was less than 5%. The median number of passes to achieve onsite diagnostic adequacy was 1 for all cohorts except when using 22G needles with suction. Also, specimen bloodiness was significantly greater when using 22G needles with suction. These observations are in line with results of a recent randomized study that reported greater specimen bloodiness when performing FNA by using the 22G needle with suction. 10 Therefore, in institutions that use ROSE, suction should be avoided if possible when performing EUS-FNA of pancreatic masses, irrespective of needle size. The use of suction makes the specimen bloodier, increases the number of passes needed to establish onsite diagnosis (particularly with 22G needles), and negatively impacts diagnostic performance. The use of suction may be considered Comparison of 4 needle/suction groups. b 5 false positives: 2 were confirmed on surgical specimens, and 3 were well on long-term follow-up without progression of disease. c 11 false negatives: 3 patients died of underlying malignancy, 5 patients had progression of disease, diagnosis was confirmed in 2 patients on surgical specimens, and 1 patient had malignancy on repeat endoscopic ultrasound-guided fine-needle aspiration. d Likelihood ratio is stated as N (infinity) when the denominator is zero.
when an FNA pass yields no specimen (dry tap), which is occasionally encountered when sampling pancreatic masses in the setting of severe chronic pancreatitis. Technical failure was significantly more frequent with the use of suction, in particular with 25G needles when performing transduodenal sampling. Use of suction increases specimen bloodiness and necessitates more FNA passes to establish onsite diagnosis, which may then lead to technical dysfunction, particularly with thin-caliber needles.
Recently, the American College of Gastroenterology Task Force on Quality in Endoscopy published quality metrics specific to sampling of pancreatic masses. 17 The key quality metrics included (1) diagnostic yield of malignancy in patients undergoing EUS-FNA of all pancreatic masses performance target of 70% and (2) sensitivity of malignancy performance target of 85%. In the present study, as reported by others, the diagnostic performance of ROSE was superior to offsite specimen (cell block) evaluation.
1 Therefore, on the basis of the results from this randomized trial, to optimize the diagnostic yield, we propose a simple algorithm for EUS-FNA of pancreatic masses according to the method of specimen evaluation (Supplementary Figure 3) . The algorithm is designed for centers that use ROSE as well as those that rely on cell block method. Because of the suboptimal tissue yield, 3 or more passes must be performed by using the 22G or 25G needle to optimize outcomes of offsite evaluation techniques. For centers that use ROSE, both 22G and 25G needles appear to perform equally well, but the use of suction should be avoided. Other proposed considerations include not using a stylet routinely because it increases specimen bloodiness and adopting the fanning maneuver because it increases cellularity and reduces the number of passes needed to achieve onsite diagnostic adequacy. 3 A major strength of our study is that we reported on the operating characteristics of EUS-FNA for both malignant and benign diseases using predefined criteria that included 12-month follow-up from the index procedure. However, some limitations of our study deserve mention. First, individual lesions were not subjected to all 4 needle/suction arms. This would mandate the performance of a minimum of 12 FNA passes per patient and hence is impractical. Second, as inherent to most endoscopic studies, double-blinding was not possible because the endosonographers could not be blinded to size of needle or use of suction. Third, although we believe that the proposed algorithm is evidence-based, it requires validation by other investigators. Fourth, we did not evaluate the newly available histology (fine-needle biopsy) needles, which are significantly more expensive and not universally available, and their role in tissue acquisition is still being evaluated. Fifth, on the basis of a Table 2 ). c On subgroup analysis, diagnostic accuracy was negatively impacted by use of suction at transduodenal passes (P ¼ .004) (Supplementary Table 2 ). d Likelihood ratio is stated as N (infinity) when the denominator is zero.
prior randomized trial showing no significant difference in the diagnostic yield of cell block between 2 and 4 passes, 13 only a finite number of passes (2) were performed for cell block in this study. However, it is possible that the diagnostic adequacy of cell block may have been higher if more dedicated passes were performed. 18 Last, we evaluated only the ROSE and cell block methods for specimen evaluation and not smear cytology technique. The latter technique mandates expertise in preparing smears and timely processing of slides, is less ideal for performing ancillary studies, and is not recommended by most pathologists.
In conclusion, the results of this randomized trial prove that outcomes of EUS-FNA are dependent on technical factors and the methods adopted for evaluating tissue specimens. Tailoring the procedural technique to the method of specimen evaluation is important to optimize the outcomes of EUS-FNA of pancreatic masses.
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